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Purpose. To evaluate our experience in preoperative radiochemotherapy (RCT) in locally advanced lung cancer followed by surgery.
Materials. Between January 2003 and July 2012, 25 eligible patients were recruited (80% male, 20% female, median age 60, with
good performance status). Most patients had scamous cell histology (48%) followed by adenocarcinomas (44%), giant cells (4%)
and 4% others. The clinical stage was 88% E.IIIA, 8% E.IIIB and 4% E.IV. 48% of patients underwent induction QT based in platinum
combined or not with taxano. All patients were treated with conformal radiotherapy, with a median dose of 6660 cGy (180cGy
daily), combined with chemotherapy. All patients had V20 less than 30%. There were 18 lobectomies, 3 bilobectomies and 4
pneumonectomies. The primary objective was overall survival (OS); secondary objectives were progression free survival (PFS),
pathologic responses and toxicity. Overall survival was analyzed with Kaplan–Meier test.
Results. At a median follow-up of 22 months, the median OS was 29 months (95% CI: 16.2–41.9) and median PFS was 23 (95%
CI: 16.1–29.9). Local progression free survival was 61 months (95% CI: 17.8–104%) and systemic progression free survival was
27.7 (CI: 9.5–45.8). Local control at 1, 2 and 3 years were 86.2%, 61.3% and 53.6% respectively. Pathologic complete response was
observed in 11 patients (47.8%) and ten patients had downstaging (43%). Induction QT did not improve the OS and PFS. During
the RCT we reported anaemia (56% G1, 4% G2), neutropaenia (20% G1, 16% G2, 8% G3), esophagitis (32% G1, 24% G2), dyspnea
(16% G1), pneumonitis (0%). There were few postoperative complications; 5 pneumothorax, 2 pleural effusion, 2 pneumonia and
1 postoperative bleeding. There was not treatment related death.
Conclusions. High dose preoperative radiochemotherapy is a feasible treatment option for lung cancer, with a high local control,
good pathologic response and long-term survival with acceptable toxicities.
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Objectives. To investigate the outcome in patients with stage III NSCLC treated with Hfx RT with and without concurrent CHT.
Methods. Hfx RT was administered to 600 patients (analysis 1) using 1.2Gy bid to a total dose of 64.8 and 69.6Gy and using
1.3Gy bid to a total of 67.6Gy. CHT consisted of Carboplatin and Etoposide. Patients with Stage IIIA, KPS 70–100 and no weight
loss > 5% were analysed separately (analysis 2). Patients with adenocarcinoma (ADC) were also analysed separately (analysis 3).
Endpoints included overall survival (OS), local progression-free survival (LPFS), distant metastasis-free survival (DMFS), toxicity
and prognostic factors.
Results. In analysis 1 (n=600), the median survival time (MST) for RT CHT and RT-only patients was 19 months and 21 months,
respectively. The RT-CHT group had signiﬁcantly better LPFS than RT group (p=0.0015), but not the DMFS (p=0.0571). In analysis 2
(n=222), MST and 5-yr OS, LPFS and DMFS rates were 33 months, 31 months and not attained yet, respectively and 36%, 43% and
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